Review of recent clinical trials and their impact on the treatment of hypercholesterolemia.

Purpose Of Review: Cardiovascular disease is the leading cause of death in the United States with incidence expected to increase in the coming decades. Recent years have produced a variety of new and novel therapeutics aimed at reducing the global burden of cardiovascular disease. This review highlights these recent advancements.

Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know.

Purpose Of Review: There have been recent developments of novel therapeutic agents for lipid lowering. This article reviews treatment concepts for two of the newest lipid-lowering medications.

Recent Findings: Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis.

Mipomersen and its use in familial hypercholesterolemia.

Familial Hypercholesterolemia (FH) is an inherited disorder characterized by a defect in the binding and internalization of low-density lipoprotein (LDL) particles, resulting in markedly elevated LDL levels and premature atherosclerosis. It is one of the most common inherited disorders of lipid metabolism. Many FH patients, especially those with homozygous FH do not reach LDL goals with traditional LDL therapies and may require additional, less often used, therapies.